Johnson & Johnson Announces Positive Late-Stage Trial Results for Psoriatic Arthritis Treatment
Johnson & Johnson (JNJ) has announced successful results from a late-stage clinical trial evaluating its therapy, Icotyde, for the treatment of psoriatic arthritis. The drug is currently FDA-approved and marketed in collaboration with Protagonist Therapeutics (PTGX) specifically for plaque psoriasis. The trial success marks a significant expansion of the potential therapeutic applications for the existing treatment. Given that approximately 30% of patients suffering from plaque psoriasis also develop psoriatic arthritis, this development positions the therapy to address a larger patient demographic and strengthens J&J's position in the immunology market.